EpiCast Report Predicts Rise in Fibromyalgia Rates
the Clinical Pain Advisor take:
The number of fibromyalgia cases is expected to increase by 0.51% by 2023, according to the Fibromyalgia EpiCast Report.
The researchers sought to create an epidemiological forecast for fibromyalgia through 2023. They defined fibromyalgia using the International Classification of Diseases, Ninth Revision (ICD-9) code for fibromyalgia (729.1) and the International Classification of Diseases, Tenth Revision (ICD-10) code for fibromyalgia (M76.7).
The researchers looked at country-specific studies to determine the risk factors and prevalence of fibromyalgia in the 7MM (United States, France, Germany, Italy, Spain, United Kingdom, and Japan).
In the 7MM, there were 23,663,533 total recorded cases of fibromyalgia in 2013. The researchers predict that by 2023, this number will rise to 24,881,838 at an Annual Growth Rate (AGR) of 0.51%. They predict that the number of cases will rise in all of the 7MM countries, excluding Germany and Japan.
The report also indicates that fibromyalgia is more prevalent in women than men. The researchers note that further studies are needed to determine the etiology of the association between gender and fibromyalgia.
In the full report, the researchers break down the 10-year epidemiology forecast of fibromyalgia, separating cases by age, gender, and pain severity. The full report is available here.
A team of epidemiologists created a forecast for fibromyalgia.
Fibromyalgia, also known as fibromyalgia syndrome and fibrositis, is a common form of nonarticular rheumatism that is associated with chronic, widespread musculoskeletal pain, generalized tender joints, fatigue, and a long list of wide-ranging symptoms, such as fatigue, sleep disturbances, irritable bowel syndrome (IBS), headaches, and depression. Fibromyalgia is a complex illness to diagnose and treat, as it is idiopathic, and its symptoms may be part of or overlap with other diseases.
For this analysis, GlobalData epidemiologists defined fibromyalgia using the International Classification of Diseases, Ninth Revision (ICD-9) code for fibromyalgia (729.1) and the International Classification of Diseases, Tenth Revision (ICD-10) code for fibromyalgia (M79.7). GlobalData epidemiologists used country-specific studies that provided the total prevalence of fibromyalgia using the 2010 American College of Rheumatology (ACR) classification criteria for this epidemiological forecast.
Clinical Pain Advisor Articles
- Cannabis Use High in Migraine
- Sustained-Release Sodium Nitrite for Diabetic Neuropathic Pain Not Associated With Headaches
- Restless Leg Syndrome, Fibromyalgia, and Depression Frequent in Migraine
- Percutaneous Electrolysis May Be Useful Adjunct for Subacromial Pain Syndrome
- Clonidine May Not Improve Post-Cesarean Delivery Analgesia
- Recommendations for Perioperative Pain Management in Patients With Opioid Tolerance
- Vertebroplasty Comparable With Placebo for Acute Vertebral Compression Fractures
- Capsaicin 8% Patch May Be Effective in Neuropathic Pain
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Prior Authorization Policy May Help Reduce Long-Acting Opioid Use
- Deaths After Nonfatal Opioid Overdose: Causes and Risk Factors
- Targeted Educational Intervention Helped Reduce Opioid Exposure in Adult Inpatients
- Systematic Cross-Checking May Reduce Medical Errors in Emergency Departments
- Corticosteroid Plus Lidocaine Injections Do Not Alleviate Pain in Central Lumbar Spinal Stenosis
- Tofacitinib May Effectively Alleviate Pain in RA, Psoriatic Arthritis, and Ankylosing Spondylitis